期刊
BREAST CANCER RESEARCH AND TREATMENT
卷 149, 期 1, 页码 69-79出版社
SPRINGER
DOI: 10.1007/s10549-014-3201-6
关键词
mTOR; PI3K; Breast; Estrogen; Anti-estrogen
类别
资金
- Norris Cotton Cancer Center Transgenics & Genetic Constructs, Pathology Translational Research, and Immunoassays & Flow Cytometry Shared Resources
- NIH [R00CA142899]
- Dartmouth College Norris Cotton Cancer Center Support Grant [P30CA023108]
- Piramal Enterprises, Ltd.
- American Cancer Society [RSG-13-292-01-TBE]
Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway has been implicated in anti-estrogen resistance in breast cancer. We tested the therapeutic potential of the novel PI3K/mTOR dual inhibitor P7170 in a panel of anti-estrogen-sensitive and anti-estrogen-resistant models of ER+ breast cancer. Estrogen receptor-positive (ER+) breast cancer cells were treated +/- P7170. Fresh cores from primary ER+/HER2- tumors from two patients were treated +/- P7170 ex vivo. Mice bearing breast cancer xenografts were randomized to treatment with vehicle, fulvestrant, P7170, or combinations, and tumor volumes were measured. Tissues and cells were analyzed for markers of pathway activity, cell viability, and apoptosis. In cell lines, P7170 exhibited IC50 values in the range of 0.9-7 nM and induced apoptosis. P7170 potently inhibited mTOR activity (a parts per thousand currency sign25 nM) and inhibited PI3K at higher concentrations (a parts per thousand yen200 nM). P7170 completely inhibited MCF-7 tumor growth, significantly inhibited growth of fulvestrant-resistant T47D tumors, and suppressed tumor cell proliferation but did not induce apoptosis. While P7170 inhibits PI3K and mTOR in ER+/HER2- human breast cancer cells and tumors ex vivo, in vivo data indicate that the primary mechanism of P7170 anti-tumor action is inhibition of mTOR and cell proliferation. P7170 is a novel agent worthy of further investigation for the treatment of ER+ breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据